Dow Jones

38 686,32

1,51%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Regulus Therapeutics Inc (RGLS)
Regulus Therapeutics Inc (RGLS) Actualités

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:RGLS

1 2 3 4 5 6 7 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
21/05/2024	22h23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
20/05/2024	22h11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RGLS	Regulus Therapeutics Inc
17/05/2024	22h02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
16/05/2024	14h00	PR Newswire (US)	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer	NASDAQ:RGLS	Regulus Therapeutics Inc
09/05/2024	22h54	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RGLS	Regulus Therapeutics Inc
09/05/2024	22h27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RGLS	Regulus Therapeutics Inc
09/05/2024	22h05	PR Newswire (US)	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
06/05/2024	14h00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
30/04/2024	14h00	PR Newswire (US)	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	NASDAQ:RGLS	Regulus Therapeutics Inc
21/03/2024	21h05	PR Newswire (US)	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
12/03/2024	11h32	PR Newswire (US)	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	NASDAQ:RGLS	Regulus Therapeutics Inc
12/03/2024	11h30	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
10/01/2024	06h15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:RGLS	Regulus Therapeutics Inc
02/01/2024	22h05	PR Newswire (US)	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
27/12/2023	22h16	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:RGLS	Regulus Therapeutics Inc
22/11/2023	14h00	PR Newswire (US)	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:RGLS	Regulus Therapeutics Inc
09/11/2023	22h05	PR Newswire (US)	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
02/11/2023	13h00	PR Newswire (US)	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
19/10/2023	14h00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
20/09/2023	13h00	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
13/09/2023	14h00	PR Newswire (US)	Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
05/09/2023	14h00	PR Newswire (US)	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences	NASDAQ:RGLS	Regulus Therapeutics Inc
23/08/2023	14h00	PR Newswire (US)	Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023	NASDAQ:RGLS	Regulus Therapeutics Inc
08/08/2023	22h05	PR Newswire (US)	Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
02/08/2023	14h00	PR Newswire (US)	Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference	NASDAQ:RGLS	Regulus Therapeutics Inc
18/07/2023	14h00	PR Newswire (US)	Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference	NASDAQ:RGLS	Regulus Therapeutics Inc
27/06/2023	14h00	PR Newswire (US)	Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
23/06/2023	22h02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:RGLS	Regulus Therapeutics Inc
23/06/2023	14h00	PR Newswire (US)	Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors	NASDAQ:RGLS	Regulus Therapeutics Inc
20/06/2023	14h00	PR Newswire (US)	Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital	NASDAQ:RGLS	Regulus Therapeutics Inc